TL;DR
Recent studies indicate that combining existing medications, including antidepressants with antipsychotics, could improve outcomes for treatment-resistant depression. These findings could influence future clinical practices.
New research indicates that combinations of existing medications may offer effective treatment options for patients with treatment-resistant depression, a condition affecting a significant portion of those with major depressive disorder.
Researchers from Harvard, Yale, and the University of Toronto analyzed data from 26 randomized controlled trials comparing intravenous ketamine with controls. They found ketamine to be more effective than placebo in rapidly reducing depressive symptoms and suicidal impulses, especially in the short term of a few days. Both ketamine and esketamine, a nasal spray version approved by the FDA, showed similar efficacy in quick symptom relief.
In addition, a meta-analysis of 22 studies examined the effectiveness of combining antidepressants with antipsychotics for treatment-resistant depression. Results indicated that some antipsychotics, such as lumapeterone, significantly improved depressive symptoms but also had higher discontinuation rates due to side effects. These findings suggest that existing medications, when used in combination, could provide new treatment pathways for patients unresponsive to standard antidepressants.
Why It Matters
This research could impact clinical practice by providing new options for treating individuals with depression that does not respond to traditional therapies. Rapid-acting drugs like ketamine and esketamine, along with effective drug combinations, may reduce the risk of suicide and improve quality of life for these patients. However, side effects and safety profiles remain important considerations.
Quality Sprays Love Nasal Spray – Fast-Acting Mood & Connection Support, Precision Metered Delivery, 10mL (70 Sprays), Premium Formula
FEEL MORE CONNECTED Designed to support emotional awareness, interpersonal connection, and overall sense of well-being.
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Background
Major depressive disorder affects millions worldwide, with at least one-third of adults not responding to at least two trials of conventional antidepressants, classifying them as having treatment-resistant depression. Ketamine was originally developed as an anesthetic but has been repurposed for depression treatment, with FDA approval for nasal esketamine. Prior studies have shown rapid symptom relief with ketamine, but long-term effects and optimal treatment combinations are still under investigation.
“At least one-third of adults with depression do not respond to at least two trials of conventional antidepressant therapies. These patients are considered to have treatment-resistant depression, and alternative therapies should be considered.”
— T. Greg Rhee, UConn School of Medicine
“These studies could potentially guide practicing psychiatrists and other clinicians to consider these new approaches of modalities for patients with moderate to severe depression, who did not previously respond to conventional antidepressant therapies.”
— T. Greg Rhee
Fluoxetine / Olanzapine (Generic for Symbyax, Oral Capsule)
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What Remains Unclear
While initial results are promising, long-term safety and efficacy of these medication combinations are still under study. It is also unclear which specific patient populations will benefit most, and how side effects will influence treatment adherence.
FDA approved esketamine for depression
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What’s Next
Further population-level epidemiologic studies are planned to evaluate the safety and effectiveness of these combination therapies. Additionally, clinical trials are expected to explore optimal dosing, duration, and patient selection criteria for these approaches.
Ketamine for Treatment-Resistant Depression: The First Decade of Progress
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
Are these medication combinations currently approved for treating depression?
While ketamine and esketamine are approved for certain depression cases, the specific combinations of antidepressants with antipsychotics are still under investigation and not yet standard practice.
What are the main side effects associated with these treatments?
Ketamine can cause dissociation and temporary blood pressure increases, while some antipsychotics may lead to side effects such as weight gain, sedation, or movement disorders. Discontinuation due to side effects has been noted in some cases.
How soon might these treatments become widely available?
Further research and clinical trials are needed before these approaches can be recommended broadly. It may take several years for regulatory approval and integration into standard care protocols.
Are there risks of dependency or abuse with ketamine-based treatments?
Ketamine has potential for abuse and dependency, which is why medical supervision and controlled use are essential. Ongoing studies aim to clarify safety profiles for therapeutic use.
